Cancer The'RBP'eutics-RNA-binding Proteins As Therapeutic Targets for Cancer

Overview

Journal Pharmacol Ther

Specialty Pharmacology

Date 2019 Jul 15

PMID 31302171

Citations 98

Authors

Shakur Mohibi

Xinbin Chen

Jin Zhang

Affiliations

Soon will be listed here.

Abstract

RNA-binding proteins (RBPs) play a critical role in the regulation of various RNA processes, including splicing, cleavage and polyadenylation, transport, translation and degradation of coding RNAs, non-coding RNAs and microRNAs. Recent studies indicate that RBPs not only play an instrumental role in normal cellular processes but have also emerged as major players in the development and spread of cancer. Herein, we review the current knowledge about RNA binding proteins and their role in tumorigenesis as well as the potential to target RBPs for cancer therapeutics.

Citing Articles

RNA-binding proteins as therapeutic targets in cancer.

Jungfleisch J, Gebauer F RNA Biol. 2025; 22(1):1-8.

PMID: 40016176 PMC: 11869776. DOI: 10.1080/15476286.2025.2470511.

Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma.

Lao Y, Jin Y, Wu S, Fang T, Wang Q, Sun L Mol Cancer. 2024; 23(1):283.

PMID: 39732660 PMC: 11681642. DOI: 10.1186/s12943-024-02199-1.

MicroRNAs and RNA-Binding Protein-Based Regulation of Bone Metastasis from Hepatobiliary Cancers and Potential Therapeutic Strategies.

Fagoonee S, Weiskirchen R Cells. 2024; 13(23).

PMID: 39682684 PMC: 11640337. DOI: 10.3390/cells13231935.

Insights into the Mode and Mechanism of Interactions Between RNA and RNA-Binding Proteins.

Fang Y, Liu X, Liu Y, Xu N Int J Mol Sci. 2024; 25(21).

PMID: 39518890 PMC: 11545484. DOI: 10.3390/ijms252111337.

Protein-RNA interaction dynamics reveal key regulators of oncogenic KRAS-driven cancers.

Ban K, Na Y, Song J, Kim J, Kim J Sci Rep. 2024; 14(1):27119.

PMID: 39511334 PMC: 11544019. DOI: 10.1038/s41598-024-78333-2.

References

Yin W, Rogge M . Targeting RNA: A Transformative Therapeutic Strategy. Clin Transl Sci. 2019; 12(2):98-112. PMC: 6440575. DOI: 10.1111/cts.12624. View

Bordeleau M, Robert F, Gerard B, Lindqvist L, Chen S, Wendel H . Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest. 2008; 118(7):2651-60. PMC: 2423864. DOI: 10.1172/JCI34753. View

He N, Jahchan N, Hong E, Li Q, Bayfield M, Maraia R . A La-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. Mol Cell. 2008; 29(5):588-99. PMC: 6239424. DOI: 10.1016/j.molcel.2008.01.003. View

Fairman-Williams M, Guenther U, Jankowsky E . SF1 and SF2 helicases: family matters. Curr Opin Struct Biol. 2010; 20(3):313-24. PMC: 2916977. DOI: 10.1016/j.sbi.2010.03.011. View

Ito Y, Narita N, Nomi N, Sugimoto C, Takabayashi T, Yamada T . Suppression of Poly(rC)-Binding Protein 4 (PCBP4) reduced cisplatin resistance in human maxillary cancer cells. Sci Rep. 2015; 5:12360. PMC: 4508830. DOI: 10.1038/srep12360. View

Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim J . Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010; 70(2):621-31. DOI: 10.1158/0008-5472.CAN-09-2340. View

Bielli P, Busa R, Paronetto M, Sette C . The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocr Relat Cancer. 2011; 18(4):R91-R102. DOI: 10.1530/ERC-11-0041. View

Shelton P, Duran A, Nakanishi Y, Reina-Campos M, Kasashima H, Llado V . The Secretion of miR-200s by a PKCζ/ADAR2 Signaling Axis Promotes Liver Metastasis in Colorectal Cancer. Cell Rep. 2018; 23(4):1178-1191. PMC: 5958623. DOI: 10.1016/j.celrep.2018.03.118. View

Jiang L, Gu Z, Yan Z, Zhao X, Xie Y, Zhang Z . Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet. 2015; 47(9):1061-6. DOI: 10.1038/ng.3358. View

10.

Braeutigam C, Rago L, Rolke A, Waldmeier L, Christofori G, Winter J . The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion. Oncogene. 2013; 33(9):1082-92. DOI: 10.1038/onc.2013.50. View

11.

Viswanathan S, Powers J, Einhorn W, Hoshida Y, Ng T, Toffanin S . Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009; 41(7):843-8. PMC: 2757943. DOI: 10.1038/ng.392. View

12.

Kang M, Ryu B, Lee M, Han J, Lee J, Ha T . NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology. 2008; 135(6):2030-42, 2042.e1-3. DOI: 10.1053/j.gastro.2008.08.009. View

13.

Liu L, Luo C, Luo Y, Chen L, Liu Y, Wang Y . MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression. Oncogene. 2017; 37(1):86-94. DOI: 10.1038/onc.2017.314. View

14.

Nabors L, Gillespie G, Harkins L, King P . HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res. 2001; 61(5):2154-61. View

15.

Pio R, Zudaire I, Pino I, Castano Z, Zabalegui N, Vicent S . Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer. Cancer Res. 2004; 64(12):4171-9. DOI: 10.1158/0008-5472.CAN-03-2982. View

16.

Gu W, Pan F, Singer R . Blocking beta-catenin binding to the ZBP1 promoter represses ZBP1 expression, leading to increased proliferation and migration of metastatic breast-cancer cells. J Cell Sci. 2009; 122(Pt 11):1895-905. PMC: 2684840. DOI: 10.1242/jcs.045278. View

17.

Bycroft M, Hubbard T, Proctor M, Freund S, Murzin A . The solution structure of the S1 RNA binding domain: a member of an ancient nucleic acid-binding fold. Cell. 1997; 88(2):235-42. DOI: 10.1016/s0092-8674(00)81844-9. View

18.

Muller S, Bley N, Glass M, Busch B, Rousseau V, Misiak D . IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic Acids Res. 2018; 46(12):6285-6303. PMC: 6158595. DOI: 10.1093/nar/gky229. View

19.

Heerma van Voss M, van Diest P, Raman V . Targeting RNA helicases in cancer: The translation trap. Biochim Biophys Acta Rev Cancer. 2017; 1868(2):510-520. PMC: 5675762. DOI: 10.1016/j.bbcan.2017.09.006. View

20.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View